OSCR

SEC source: 0000899243-21-034960 · doc4.xml · derivative · entry 5

Joyce Meghan V. · CIK 0001770749 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 263,210

Underlying: Class A Common Stock · 263,210 shares

Expires 2031-08-31

F5 · derivative.exercise_date: The options will vest over a four-year period in 16 equal quarterly installments beginning on December 1, 2021.

SEC source: 0000899243-21-034960 · doc4.xml · derivative · entry 4

Joyce Meghan V. · CIK 0001770749 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,251

Underlying: Class A Common Stock · 112,251 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

F4 · derivative.exercise_date: The restricted stock units will vest over a four-year period in 16 equal quarterly installments beginning on December 1, 2021.

F4 · derivative.expiration_date: The restricted stock units will vest over a four-year period in 16 equal quarterly installments beginning on December 1, 2021.

SEC source: 0000899243-21-034957 · doc4.xml · derivative · entry 4

Weaver Dennis · CIK 0001844219 · Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 263,210

Underlying: Class A Common Stock · 75,202 shares

Expires 2031-08-31

F5 · derivative.exercise_date: The options will vest over a four-year period in 16 equal quarterly installments beginning on December 1, 2021.

SEC source: 0000899243-21-034957 · doc4.xml · derivative · entry 3

Weaver Dennis · CIK 0001844219 · Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,251

Underlying: Class A Common Stock · 32,072 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

F4 · derivative.exercise_date: The restricted stock units will vest over a four-year period in 16 equal quarterly installments beginning on December 1, 2021.

F4 · derivative.expiration_date: The restricted stock units will vest over a four-year period in 16 equal quarterly installments beginning on December 1, 2021.

SEC source: 0000899243-21-034820 · doc4.xml · nonDerivative · entry 2

Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner

Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner

Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner

Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,052,864

F3 · shares: Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII.

F3 · price: Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII.

F3 · balance_after: Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034820 · doc4.xml · nonDerivative · entry 1

Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner

Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner

Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner

Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,997,676

F1 · shares: Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII.

F1 · price: Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII.

F1 · balance_after: Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034817 · doc4.xml · nonDerivative · entry 2

Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,052,864

F3 · shares: Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII.

F3 · price: Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII.

F3 · balance_after: Represents (i) 54,531 shares purchased by Thrive VII Growth and (ii) 657 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,028,425 shares are held directly by Thrive VII Growth and 24,439 shares are held directly by Claremount VII.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034817 · doc4.xml · nonDerivative · entry 1

Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,997,676

F1 · shares: Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII.

F1 · price: Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII.

F1 · balance_after: Represents (i) 271,427 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 3,270 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,973,894 shares are held directly by Thrive VII Growth and 23,782 shares are held directly by Claremount VII.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034460 · doc4.xml · nonDerivative · entry 3

Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner

Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner

Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner

Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,722,979

F4 · shares: Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII.

F4 · price: Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII.

F4 · balance_after: Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034462 · doc4.xml · nonDerivative · entry 3

Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,722,979

F4 · shares: Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII.

F4 · price: Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII.

F4 · balance_after: Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034460 · doc4.xml · nonDerivative · entry 2

Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner

Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner

Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner

Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,505,389

F3 · shares: Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII.

F3 · price: Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII.

F3 · balance_after: Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034462 · doc4.xml · nonDerivative · entry 2

Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,505,389

F3 · shares: Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII.

F3 · price: Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII.

F3 · balance_after: Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034460 · doc4.xml · nonDerivative · entry 1

Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner

Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner

Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner

Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,300,578

F1 · shares: Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII.

F1 · price: Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII.

F1 · balance_after: Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034462 · doc4.xml · nonDerivative · entry 1

Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,300,578

F1 · shares: Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII.

F1 · price: Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII.

F1 · balance_after: Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034081 · doc4.xml · nonDerivative · entry 3

Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner

Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner

Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner

Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,268,784

F4 · shares: Represents (i) 1,061,552 shares purchased by Thrive VII Growth and (ii) 12,790 shares purchased by Claremount VII. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034083 · doc4.xml · nonDerivative · entry 3

Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,268,784

F4 · shares: Represents: (i) 1,061,552 shares of Class A common stock purchased by Thrive VII Growth and (ii) 12,790 shares of Class A common stock purchased by Claremount VII. All shares were purchased in accordance with the daily volume and other limitations of Rule 10b-18.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034081 · doc4.xml · nonDerivative · entry 2

Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner

Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner

Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner

Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 194,442

F3 · shares: Represents (i) 124,401 shares purchased by Thrive VII Growth and (ii) 1,499 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $12.83 to $13.29, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18.

F3 · price: Represents (i) 124,401 shares purchased by Thrive VII Growth and (ii) 1,499 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $12.83 to $13.29, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034083 · doc4.xml · nonDerivative · entry 2

Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 194,442

F3 · shares: Represents: (i) 124,401 shares of Class A common stock purchased by Thrive VII Growth and (ii) 1,499 shares of Class A common stock purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.83 to $13.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations of Rule 10b-18.

F3 · price: Represents: (i) 124,401 shares of Class A common stock purchased by Thrive VII Growth and (ii) 1,499 shares of Class A common stock purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.83 to $13.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations of Rule 10b-18.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034081 · doc4.xml · nonDerivative · entry 1

Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner

Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner

Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner

Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 68,542

F1 · shares: Represents (i) 67,232 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 810 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.12 to $13.53, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18.

F1 · price: Represents (i) 67,232 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 810 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $13.12 to $13.53, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0000899243-21-034083 · doc4.xml · nonDerivative · entry 1

Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 68,542

F1 · shares: Represents: (i) 67,726 shares of Class A common stock purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 816 shares of Class A common stock purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.12 to $13.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations of Rule 10b-18.

F1 · price: Represents: (i) 67,726 shares of Class A common stock purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 816 shares of Class A common stock purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.12 to $13.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations of Rule 10b-18.

F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.

SEC source: 0001562180-21-005496 · primarydocument.xml · derivative · entry 2

KLEIN JOEL · CIK 0001166832 · Chief Policy & Strat. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 17 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

F2 · derivative.exercise_date: On March 5, 2021, the reporting person received a grant of 17 RSUs, all of which vested on August 18, 2021.

F2 · derivative.expiration_date: On March 5, 2021, the reporting person received a grant of 17 RSUs, all of which vested on August 18, 2021.

SEC source: 0001562180-21-005496 · primarydocument.xml · nonDerivative · entry 1

KLEIN JOEL · CIK 0001166832 · Chief Policy & Strat. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

SEC source: 0001562180-21-005497 · primarydocument.xml · derivative · entry 2

Schlosser Mario · CIK 0001844320 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 17 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

F2 · derivative.exercise_date: On March 5, 2021, the reporting person received a grant of 17 RSUs, all of which vested on August 18, 2021.

F2 · derivative.expiration_date: On March 5, 2021, the reporting person received a grant of 17 RSUs, all of which vested on August 18, 2021.

SEC source: 0001562180-21-005497 · primarydocument.xml · nonDerivative · entry 1

Schlosser Mario · CIK 0001844320 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

SEC source: 0001562180-21-005498 · primarydocument.xml · derivative · entry 2

Weaver Dennis · CIK 0001844219 · Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 17 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

F2 · derivative.exercise_date: On March 5, 2021, the reporting person received a grant of 17 RSUs, all of which vested on August 18, 2021.

F2 · derivative.expiration_date: On March 5, 2021, the reporting person received a grant of 17 RSUs, all of which vested on August 18, 2021.

SEC source: 0001562180-21-005498 · primarydocument.xml · nonDerivative · entry 1

Weaver Dennis · CIK 0001844219 · Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

SEC source: 0001562180-21-005495 · primarydocument.xml · derivative · entry 3

Joyce Meghan V. · CIK 0001770749 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 17 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

F2 · derivative.exercise_date: On March 5, 2021, the reporting person received a grant of 17 RSUs, all of which vested on August 18, 2021.

F2 · derivative.expiration_date: On March 5, 2021, the reporting person received a grant of 17 RSUs, all of which vested on August 18, 2021.

SEC source: 0001562180-21-005495 · primarydocument.xml · nonDerivative · entry 1

Joyce Meghan V. · CIK 0001770749 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

SEC source: 0001562180-22-001250 · primarydocument.xml · nonDerivative · entry 2

Sankaran Sid · CIK 0001509066 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Victoria Family LLC

Disclosed balance after: 499,999

F1 · shares: On August 3, 2021, the reporting person transferred 166,666 shares of common stock to the Victoria Family LLC, of which the reporting person is Investment Adviser.

F2 · ownership.nature: Victoria Family LLC is wholly owned by the fiduciaries of The Victoria 2020 Trust. Mr. Sankaran is the Investment Adviser to The Victoria 2020 Trust. Mr. Sankaran disclaims beneficial ownership of the shares held of record by Victoria Family LLC except to the extent of his pecuniary interests therein.

SEC source: 0001562180-22-001250 · primarydocument.xml · nonDerivative · entry 1

Sankaran Sid · CIK 0001509066 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: On August 3, 2021, the reporting person transferred 166,666 shares of common stock to the Victoria Family LLC, of which the reporting person is Investment Adviser.

SEC source: 0000899243-21-010170 · doc4.xml · derivative · entry 2

KLEIN JOEL · CIK 0001166832 · Chief Policy & Strat. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17

Underlying: Class A Common Stock · 17 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

F2 · derivative.exercise_date: The restricted stock units vest upon the earlier of (i) 180 days after the IPO date, or (ii) the second day following the expiration of the underwriter-mandated lock-up period associated with the Issuer's initial public offering.

F2 · derivative.expiration_date: The restricted stock units vest upon the earlier of (i) 180 days after the IPO date, or (ii) the second day following the expiration of the underwriter-mandated lock-up period associated with the Issuer's initial public offering.

SEC source: 0000899243-21-010170 · doc4.xml · nonDerivative · entry 1

KLEIN JOEL · CIK 0001166832 · Chief Policy & Strat. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0000899243-21-010188 · doc4.xml · derivative · entry 6

Schlosser Mario · CIK 0001844320 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pizzo-Schlosser 2020 GRAT and Spousal Trust

Disclosed balance after: 956,744

Underlying: Class A Common Stock · 219,772 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Class B common stock is convertible at any time at the option of the holder into Class A common stock on a one-to-one basis, subject to certain exceptions, and will mandatorily convert into Class A common stock on the date that is seven years from the date of the prospectus used in connection with the Issuer's initial public offering and upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation.

F1 · price: The Class B common stock is convertible at any time at the option of the holder into Class A common stock on a one-to-one basis, subject to certain exceptions, and will mandatorily convert into Class A common stock on the date that is seven years from the date of the prospectus used in connection with the Issuer's initial public offering and upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation.

F1 · derivative.exercise_date: The Class B common stock is convertible at any time at the option of the holder into Class A common stock on a one-to-one basis, subject to certain exceptions, and will mandatorily convert into Class A common stock on the date that is seven years from the date of the prospectus used in connection with the Issuer's initial public offering and upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation.

F1 · derivative.expiration_date: The Class B common stock is convertible at any time at the option of the holder into Class A common stock on a one-to-one basis, subject to certain exceptions, and will mandatorily convert into Class A common stock on the date that is seven years from the date of the prospectus used in connection with the Issuer's initial public offering and upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation.

F2 · ownership.nature: Mr. Schlosser disclaims beneficial ownership over the shares held of record by the trust except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-21-010188 · doc4.xml · derivative · entry 5

Schlosser Mario · CIK 0001844320 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17

Underlying: Class A Common Stock · 17 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

F6 · derivative.exercise_date: The restricted stock units vest upon the earlier of (i) 180 days after the IPO date, or (ii) the second day following the expiration of the underwriter-mandated lock-up period associated with the Issuer's initial public offering.

F6 · derivative.expiration_date: The restricted stock units vest upon the earlier of (i) 180 days after the IPO date, or (ii) the second day following the expiration of the underwriter-mandated lock-up period associated with the Issuer's initial public offering.

SEC source: 0000899243-21-010188 · doc4.xml · derivative · entry 4

Schlosser Mario · CIK 0001844320 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,229,853

Underlying: Class A Common Stock · 4,229,853 shares

Expires 2028-03-05

F3 · derivative.exercise_price: Each performance restricted stock unit represents a contingent right to receive one share of Class A common stock.

F4 · derivative.exercise_date: The performance restricted stock units vest upon the Issuer's common stock achieving certain specified price per share targets ranging from $90 to $270 per share.

SEC source: 0000899243-21-010188 · doc4.xml · nonDerivative · entry 3

Schlosser Mario · CIK 0001844320 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pizzo-Schlosser 2020 GRAT and Spousal Trust

Disclosed balance after: 0

F2 · ownership.nature: Mr. Schlosser disclaims beneficial ownership over the shares held of record by the trust except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-21-010188 · doc4.xml · nonDerivative · entry 2

Schlosser Mario · CIK 0001844320 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Pizzo-Schlosser 2020 GRAT and Spousal Trust

Disclosed balance after: 219,772

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Class B common stock is convertible at any time at the option of the holder into Class A common stock on a one-to-one basis, subject to certain exceptions, and will mandatorily convert into Class A common stock on the date that is seven years from the date of the prospectus used in connection with the Issuer's initial public offering and upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation.

F2 · ownership.nature: Mr. Schlosser disclaims beneficial ownership over the shares held of record by the trust except to the extent of his pecuniary interest therein, if any.

SEC source: 0000899243-21-010188 · doc4.xml · nonDerivative · entry 1

Schlosser Mario · CIK 0001844320 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0000899243-21-010209 · doc4.xml · nonDerivative · entry 1

PHILLIPS JR CHARLES E · CIK 0001236185 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: Represents an award of restricted stock units that vest in three equal annual installments beginning on March 5, 2022.

SEC source: 0000899243-21-010185 · doc4.xml · nonDerivative · entry 1

WITTMAN VANESSA AMES · CIK 0001229265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: Represents an award of restricted stock units that vest in three equal annual installments beginning on March 5, 2022.

SEC source: 0000899243-21-010182 · doc4.xml · derivative · entry 3

Sankaran Sid · CIK 0001509066 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17

Underlying: Class A Common Stock · 17 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

F3 · derivative.exercise_date: The restricted stock units vest upon the earlier of (i) 180 days after the IPO date, or (ii) the second day following the expiration of the underwriter-mandated lock-up period associated with the Issuer's initial public offering.

F3 · derivative.expiration_date: The restricted stock units vest upon the earlier of (i) 180 days after the IPO date, or (ii) the second day following the expiration of the underwriter-mandated lock-up period associated with the Issuer's initial public offering.

SEC source: 0000899243-21-010182 · doc4.xml · nonDerivative · entry 1

Sankaran Sid · CIK 0001509066 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,666

SEC source: 0000899243-21-010174 · doc4.xml · nonDerivative · entry 1

List Teri · CIK 0001529370 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: Represents an award of restricted stock units that vest in three equal annual installments beginning on March 5, 2022.

SEC source: 0000899243-21-010192 · doc4.xml · derivative · entry 1

Kushner Joshua · CIK 0001844181 · Director · Vice Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,114,926

Underlying: Class A Common Stock · 2,114,926 shares

Expires 2028-03-05

F1 · derivative.exercise_price: Each performance restricted stock unit represents a contingent right to receive one share of Class A common stock.

F2 · derivative.exercise_date: The performance restricted stock units vest upon the Issuer's common stock achieving certain specified price per share targets ranging from $90 to $270 per share.

SEC source: 0000899243-21-010186 · doc4.xml · nonDerivative · entry 1

Robinson Elbert O. Jr. · CIK 0001844223 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: Represents an award of restricted stock units that vest in three equal annual installments beginning on March 5, 2022.

SEC source: 0000899243-21-010180 · doc4.xml · nonDerivative · entry 1

Plouffe David · CIK 0001844229 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: Represents an award of restricted stock units that vest in three equal annual installments beginning on March 5, 2022.

SEC source: 0000899243-21-010176 · doc4.xml · derivative · entry 3

Weaver Dennis · CIK 0001844219 · Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,667

Underlying: Class A Common Stock · 66,667 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

F3 · derivative.exercise_date: The restricted stock units vest in sixteen equal quarterly installments beginning on June 1, 2021.

F3 · derivative.expiration_date: The restricted stock units vest in sixteen equal quarterly installments beginning on June 1, 2021.

SEC source: 0000899243-21-010176 · doc4.xml · derivative · entry 2

Weaver Dennis · CIK 0001844219 · Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17

Underlying: Class A Common Stock · 17 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

F2 · derivative.exercise_date: The restricted stock units vest upon the earlier of (i) 180 days after the IPO date, or (ii) the second day following the expiration of the underwriter-mandated lock-up period associated with the Issuer's initial public offering.

F2 · derivative.expiration_date: The restricted stock units vest upon the earlier of (i) 180 days after the IPO date, or (ii) the second day following the expiration of the underwriter-mandated lock-up period associated with the Issuer's initial public offering.

SEC source: 0000899243-21-010176 · doc4.xml · nonDerivative · entry 1

Weaver Dennis · CIK 0001844219 · Chief Clinical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0000899243-21-010169 · doc4.xml · derivative · entry 3

Joyce Meghan V. · CIK 0001770749 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17

Underlying: Class A Common Stock · 17 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

F2 · derivative.exercise_date: The restricted stock units vest upon the earlier of (i) 180 days after the IPO date, or (ii) the second day following the expiration of the underwriter-mandated lock-up period associated with the Issuer's initial public offering.

F2 · derivative.expiration_date: The restricted stock units vest upon the earlier of (i) 180 days after the IPO date, or (ii) the second day following the expiration of the underwriter-mandated lock-up period associated with the Issuer's initial public offering.